Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma

Inclusion Criteria: * first relapse or primary refractory disease of aggressive Non-Hodgkin's lymphoma stage I-IV * pretreatment with systemic therapy * 18-65 years of age * Performance status:ECOG 0-2 * Granulocyte count \>1.5/µm3, Platelet count \>100/µm3 * Creatinine -Clearance ≥ 1 ml/sec * GPT/GOT ≤ 1.5 x normal (except tumour related) * Bilirubine \< 22 µmol/l * no participation in another study 3 month before and during this study * informed consent Exclusion Criteria: * Second neoplasia in history or existing except basalioma or squamous epithelium carcinoma of the skin or removed cervical intraepithelial neoplasia * CNS- involvement by lymphoma * respiratory Partial- or global insufficiency * cardiac insufficiency (NYHA-Stage 3-4, EF \< 30 %) * severe neurological or psychiatric disease * pregnancy * HIV positivity ,active virus hepatitis, bacterial infection * No follow up procedures ensured